LYEL

$15.00-2.79%visit website

Lyell Immunopharma, Inc.

Market Cap

$369M

Live price × SEC shares (Oct 30, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

-0.02

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Sep 2026 · negative earnings

P/S (TTM)

24585.6

TTM to Sep 2026 · revenue

P/B

1.9

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	Q3 FY2026 Sep 30, 2026	TTM Sep 30, 2026
Revenue	6.0	2.0	4.0	3.0	15.0
Research & development		36,604	39,524	40,898
Total operating expenses	127,650	44,263	47,341	48,298	267,552
Operating income	(127,644)	(44,261)	(47,337)	(48,295)	(267,537)
Net income	(140,723)	(24,153)	(44,755)	(45,529)	(255,160)
EPS (basic) ($)		(1.10)	(1.92)	(1.86)	—
EPS (diluted) ($)		(1.10)	(1.92)	(1.86)	—
Weighted avg. shares (basic)		21,876	23,364	24,436
Weighted avg. shares (diluted)		21,876	23,364	24,436

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Nov 4, 2026, period ended Sep 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 22 more quarters, back to Jun 2020, with Tormere Pro.

Corporate Events (8-K)

2 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Nov 4, 2026 accepted 4:14 PM ET	2.02Earnings release	Document SEC ↗
Nov 4, 2026 accepted 9:05 AM ET	3.02Unregistered equity sale	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

47%

W/W +4.4pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Velocity Score

7.59x

Avg Daily Selling (90d)

158 sh/day

Baseline Daily Selling

57.6 sh/day

Unique Sellers (90d)

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-10-12	2026-10-13	Aguirre Jarrad Mattieu	Chief Medical Officer	Sale	422	$8.63	$4K	19.9K	View
2026-09-10	2026-09-10	Shook David	Chief Medical Officer	Sale	500	$12.70	$6K	20.4K	View
2026-08-21	2026-08-25	Lee Gary K.	Chief Scientific Officer	Sale	1,457	$15.54	$23K	16.2K	View
2026-08-21	2026-08-25	Hill Stephen J.	Chief Operating Officer	Sale	989	$15.54	$15K	16.8K	View
2026-08-21	2026-08-25	Seely Lynn	Director & President and CEO	Sale	9,589	$15.54	$149K	63.9K	View

1–5 of 25

1 / 5

Recent News

Lyell Immunopharma: Q3 Earnings Snapshot

Yahoo · 2026-11-04

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026

Yahoo · 2026-11-04

In a lymphoma trial, 91% of 44 patients responded to treatment; 77% had complete responses.

Stock Titan · 2026-11-04

Today's US Session Top Gainers and Losers: TNONW and CENN Lead

ChartMill · 2026-11-04

Top U.S. Stock Movers: Nov. 4, 2026 Gainers and Losers

ChartMill · 2026-11-04

12 Health Care Stocks Moving In Wednesday's Intraday Session

Benzinga · 2026-11-04

What Is Lifting Lyell Immunopharma (NASDAQ:LYEL) Shares 32.59% Higher Following an USD 80 Million Placement?

kalkine.ca · 2026-11-04

US Gap Movers for Nov. 4, 2026: Sharp Opens in Both Directions

ChartMill · 2026-11-04

Lyell Immunopharma raises $80 million in private placement By Investing.com

Investing.com UK · 2026-11-04

Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission

Yahoo · 2026-11-04

An approximately $80 million stock sale is expected to help fund Lyell's cancer trials into 2028.

Stock Titan · 2026-11-04

Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Yahoo · 2026-11-04

Lyell Immunopharma Announces ~$80M Private Placement Of 7.4M Shares At $10.77/Share

Benzinga · 2026-11-04

Lyell Immunopharma Announces That Two Abstracts Featuring Updated Clinical Data For Rondecabtagene Autoleucel Have Been Accepted To The American Society Of Hematology Meeting, December 12–15; Ronde-Cel Achieved 91% Overall Response Rate And 77% Complete Response Rate

Benzinga · 2026-11-04

Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target

Benzinga · 2026-11-03

Informational purposes only, not investment advice.

LYEL

Financial Statements

Corporate Events (8-K)

Signals

Factor Profile

Recent News

Lyell Immunopharma, Inc. (LYEL)

Reporting Insiders

Factor Profile

Corporate Events (8-K)

Date	Insider	Type	Shares	Value
2026-10-12	Aguirre Jarrad Mattieu	S	422	$3,641.86
2026-09-10	Shook David	S	500	$6,350
2026-08-21	Lee Gary K.	S	1,457	$22,641.78
2026-08-21	Hill Stephen J.	S	989	$15,369.06
2026-08-21	Seely Lynn	S	9,589	$149,013.06